rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 124 125 126 127 128 ... 179 »» | Laatste | Omlaag ↓
  18. [verwijderd] 14 juni 2007 10:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    succes dan yank. , we zijn geslotemn op DH van de dag er voor, dus kan ook zijn dat we vanaf hier weer een trede omhoog gaan, en sluiten op DH van gisteren, rond 2.14
  19. [verwijderd] 14 juni 2007 10:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    www.streetinvesting.com: Market Review on Generex Biotechnology Corporation
    via COMTEX

    June 14, 2007

    Jun 14, 2007 (M2 PRESSWIRE via COMTEX News Network) --

    Please visit www.Streetinvesting.com for the full report, additional research and related articles on the company mentioned herein.

    Wall Street, still intoxicated by inflation chitchats, is swinging uncomfortably between a continuous bearish bearing and a much awaited bull-pull this Tuesday. With investors mind's clinging on prospect that economic data on the inflation would be available by the end of this week, the market is set for another day of sell off. The feeling on the Street looks more like a preparation for the worst. Any unfavorable economic data, as it drops in investors ears, bring along a sense of concern. The bears are looking for more grounds to rule and the economy, as it stands, is providing them momentum. Generex Biotechnology Corporation (NASDAQ: GNBT) finished with sky rocketing $1.80 and an amazing trading volume of 19,439,718 this Tuesday.

    With our experienced team of researchers employing expertise and effort on the understanding of prospective companies listed on NASDAQ, we bring forward to your attention Generex Biotechnology Corporation.

    Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced, in a press release on Tuesday June 12, 2007, that Rodman & Renshaw, a New York-based investment bank, initiated coverage of the Company with a "Market Outperform" rating and an 18-month price target of $6.00. The report was issued by Navdeep S. Jaikaria, Ph.D., a Managing Director in the Equity Research Division.

    The reported noted that, "Our analysis indicates that Generex's oral insulin, Oral-lyn, could be a significant player in the non-injectable insulin market. We believe that Oral-lyn's product profile, combined with strong clinical data and expected rapid growth in the global diabetic population, could result in > $600 MM in revenues by 2013. Generex also has two other smaller products in diabetes and an early-stage cancer vaccine pipeline."

    The report also stated that, "We believe that Generex's Oral-lyn has advantages over other non-injectable insulin solutions. While many of these systems deliver insulin to the lungs and bronchial tree, Oral-lyn delivers insulin to the oral mucosa, avoiding the potential risks of chronic lung tissue exposure to insulin. Additionally, pharmacokinetic studies have shown that Oral-lyn reaches peak circulating levels in 30 minutes compared to 60 minutes with injected insulin. This more rapid onset will offer patients a better quality of life by providing more flexibility at meal times, and better glycemic control."

    Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. Rodman employs dedicated, experienced, and talented professionals within its equity research, corporate finance, and sales & trading divisions.

    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. The Company's flagship product, oral insulin (Generex Oral-lyn), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.

    As Bond yields makes a surge well beyond last summer's estimates and US equities still sinking, Streetinvesting.com will take a probing look into the future of Generex Biotechnology Corporation. Our team is restlessly on the prowl for more news and development that would help you comprehend the intrinsic mechanisms of the market and its affect on this company.

    Please visit www.streetinvesting.com for a complimentary subscription to access this issuance and other related in-depth articles. Please note that membership does not require credit card information nor does it require a commitment to our service.

    We have initiated this news release as a tool to keep investors informed about the market. The information contained herein comes from an unbiased perspective and we do not have a vested interest in the companies mentioned in this release. Becoming a member to www.streetinvesting.com will give you access to all the on-going information and investment news that we come across.

    Investors wishing to seek a different approach to their investment theories and concepts and to be informed of unique investment opportunities should also visit www.streetinvesting.com for a free membership.

    About Street Investing

    Streetinvesting.com has now become a leading online financial newsletter community with thousands of investors from around the world. Our goal is to bring our theories and techniques to investors seeking a different and unique approach to investment ideas. We have a research team that has been built upon the premise of finding companies that we feel may interest investors looking for that unique and tactical edge. More information can be found on our website at www.streetinvesting.com

    If you have been brought here under false pretense, please let our staff know by emailing us at support@streetinvesting.com. Please feel free to visit our site for more information and a free membership.

    This news release shall not constitute an offer to sell or the solic
  20. [verwijderd] 14 juni 2007 10:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ja dat is wel zo maar wat ik zei de 1,95-2$ is erg belangrijk. Hij is voor de zoveelste keer weer afgeketst. Als ie vandaag tussen de 1,70-1,90 gaat schommelen dan is dat een slecht teken.
  21. [verwijderd] 14 juni 2007 11:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Yankee

    Er is niets wat in 1 streep omhoog gaat .
    Er zijn altijd wat hindernisjes onderweg.

    Feit is dat GNBT weer mooi op de kaart staat in USA .
    Er zullen ook nog wel wat vakbeleggingsbladen aandacht aan gaan geven .

    Nu maar hopen dat shorters het aandeel links laten liggen,omdat de kans op een stijging groter aan het worden is .

    13 maanden geleden stond het aandeel op 4$ + . Nu nog geen 2 $ .

    Er is dus voldoende ruimt naar boven (naar de 6$ )
    hoppaaaaaaa
3.572 Posts
Pagina: «« 1 ... 124 125 126 127 128 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.019
AB InBev 2 5.506
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.705
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.714
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.866
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.339
Air France - KLM 1.025 35.047
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.886
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.274
AMG 971 133.496
AMS 3 73
Amsterdam Commodities 305 6.691
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.009
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.781
Arcelor Mittal 2.033 320.724
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.306
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.192
ASML 1.766 107.585
ASR Nederland 21 4.498
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.675
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392